# Amunix Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amunix-pharmaceuticals

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.amunix.com
- Total disclosed funding: $201M
- Latest round: Series B (Feb 26, 2021)
- Investors on record: 18

## About

Founded in 2006 and based in California, US, Amunix Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded by Volker Schellenberger. In March 2021, Amunix raised USD 117 million in Series B funding led by Viking Global Investors.

Amunix is a biopharmaceutical company that focuses on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers. Amunix offers XPAT® and XPAC™ technology platforms to develop novel drugs that are preferentially activated in the tumor microenvironment and designed to overcome toxicity challenges that have hindered other T cell and cytokine therapies. Amunix's pipeline includes AMX-818, an XPAT® T cell engager targeting a variety of HER2-expressing solid tumors, which is currently in IND-enabling studies. Along with several other T cell engager programs, the company is also applying its proprietary masking technology to its first masked, protease-activated cytokine program, IL12-XPAC™, which is in the discovery stage.

The company plans to continue developing AMX-818, a masked, protease-activated T cell engager (XPAT®) targeting HER2-expressing solid tumors, as well as support Amunix’s pipeline of earlier-stage XPATs® and masked, protease-activated cytokines (XPACs™).

## Funding rounds

- Series B, Feb 26, 2021, $117M — Frazier Healthcare Partners, Bain Capital, Polaris Partners, Venrock, Viking Global Investors, Longitude Capital, Clough Capital, ArrowMark Partners, Omega Funds, BlackRock, Redmile Group, Casdin Capital, Franklin Templeton, Janus Henderson Investors, Avidity Partners Management, CaaS Capital Management
- Series A, Feb 28, 2020, $84M — Frazier Healthcare Partners, Polaris Partners, Venrock, Longitude Capital, Omega Funds, Redmile Group, Casdin Capital, Delian Capital, Two River

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- Venrock (https://capitalatlas.ai/funds/venrock) — Series A, Series B
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A, Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A, Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series A, Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A, Series B
- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Series A
- Two River (https://capitalatlas.ai/funds/two-river) — Series A
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- Clough Capital — Series B
- ArrowMark Partners — Series B
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series B
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series B
- Janus Henderson Investors — Series B
- Avidity Partners Management — Series B
- CaaS Capital Management (https://capitalatlas.ai/funds/caas-capital-management) — Series B